Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
Vendel A. Kristensen, Randi Opheim, Gøri Perminow, Gert Huppertz‐Hauss, Trond Espen Detlie, Charlotte Lund, Svend Andersen, Bjørn C. Olsen, Ingunn Johansen, Asle W. Medhus, Simen Vatn, Stephan Brackmann, Christine Olbjørn, Jon Rove, Magne Henriksen, Emma E. Løvlund, May‐Bente Bengtson, Tone Bergene Aabrekk, Tor Inge Tønnessen, Florin B. Vikskjold, Hussain Yassin, Svein Oskar Frigstad, Audun Hasund, Ole Høie, Katharina Schmidt, Raziye Boyar Cetinkaya, Roald Torp, Erik Skogestad, H. K. Holm, Tahir Riaz Ahmad, Øistein Hovde, Carl Magnus Ystrøm, Batool Aballi, Arnt Sagosen, A. R. Pedersen, Stein Dahler, Jens Pallenschat, Petr Ricanek, Marte Lie Høivik
Abstract
BACKGROUND AND AIM: Modern treatment strategies for inflammatory bowel disease (IBD) are postulated to change the natural disease course. Inception cohort studies are the gold standard for investigating such changes. We have initiated a new population-based inception cohort study; Inflammatory bowel disease in South Eastern Norway III (IBSEN III). In this article, we describe the study protocol and baseline characteristics of the cohort. METHODS: IBSEN III is an ongoing, population-based observational inception cohort study with prospective follow-up. Adult and pediatric patients with suspected IBD in the South-Eastern Health Region of Norway (catchment area of 2.95 million inhabitants in 2017), during the 3-year period from 2017 to 2019, were eligible for inclusion. Comprehensive clinical, biochemical, endoscopic, demographic, and patient-reported data were collected at the time of diagnosis and throughout standardized follow-up. For a portion of the patients, extensive biological material was biobanked. RESULTS: The study included 2168 patients, of whom 1779 were diagnosed with IBD (Crohn's disease: 626, ulcerative colitis: 1082, IBD unclassified: 71). In 124 patients, there were subtle findings indicative of, but not diagnostic for, IBD. The remaining 265 patients were classified as symptomatic non-IBD controls. CONCLUSION: We have included patients in a comprehensive population-based IBD cohort from a catchment population of 2.95 million, and a unique biobank with materials from newly diagnosed and treatment-naïve IBD patients and symptomatic non-IBD controls. We believe this cohort will add important knowledge about IBD in the years to come.